"When you hear that you have cancer, it changes everything. It’s a diagnosis that can break your heart and turn your world upside down. At Providence, you’re never alone in this journey. The Providence St. Mary Regional Cancer Center in Walla Walla is exclusively devoted to comprehensive cancer care. Our doctors, nurses and other specialists will give you the best-possible support, therapies and care, whatever type or stage of cancer you have. Your care team includes specialty-trained doctors who cooperate to diagnose and treat common and rare cancers. Your cancer team will work closely with you and your family, too. We’ll plan effective treatments to help you feel better and realize the best-possible long-term outcomes."

During the past decade, Providence Saint Mary Regional Cancer Center conducted 147 clinical trials. In the 10-year time frame, 147 clinical trials started and 66 clinical trials were completed, i.e. on average, 44.9% percent of trials that started reached the finish line to date. In the past 5 years, 62 clinical trials started and 54 clinical trials were completed. i.e. 87.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Saint Mary Regional Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 91 trials, followed by "Alliance for Clinical Trials in Oncology" with 33 trials sponsored, "SWOG Cancer Research Network" with 31 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 15 trials sponsored and "GOG Foundation" with 15 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Saint Mary Regional Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 101 trials as a collaborator, "NRG Oncology" with 22 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Providence Saint Mary Regional Cancer Center" are "Recurrent Ovarian Carcinoma" (11 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Invasive Breast Carcinoma" (8 trials), "Ovarian Seromucinous Carcinoma" (8 trials) and "Recurrent Fallopian Tube Carcinoma" (8 trials). Many other conditions were trialed in "Providence Saint Mary Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "Providence Saint Mary Regional Cancer Center" are "Drug" (157 trials), "Other" (115 trials), "Biological" (84 trials), "Procedure" (52 trials) and "Radiation" (26 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (57 trials), "Quality-of-Life Assessment" (50 trials), "Paclitaxel" (33 trials), "Questionnaire Administration" (32 trials) and "Computed Tomography" (31 trials). Other intervention names were less common.

The vast majority of trials in "Providence Saint Mary Regional Cancer Center" are 148 trials for "All" genders, 40 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Saint Mary Regional Cancer Center". undefined are not yet recruiting, 58 are recruiting, 92 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Providence Saint Mary Regional Cancer Center, 7 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Saint Mary Regional Cancer Center, 5 "Phase 1" clinical trials were conducted, 100 "Phase 2" clinical trials and 96 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".